A Retrospective Analysis of Micafungin Prophylaxis in Children Under 12 Years Undergoing Chemotherapy or Hematopoietic Stem Cell Transplantation
- 1 August 2024
- journal article
- Published by The Pediatric Pharmacy Association in The Journal of Pediatric Pharmacology and Therapeutics
- Vol. 29 (4) , 379-384
Abstract
OBJECTIVES: Literature is limited regarding ideal micafungin dosing in pediatric patients with hematologic malignancies receiving chemotherapy or hematopoietic stem cell transplantation. Micafungin is an intravenous echinocandin with activity against Candida and Aspergillus species and has a favorable safety profile compared with other antifungal classes. Our objective was to evaluate the breakthrough invasive fungal infection (IFI) rate in pediatric patients who received a prophylactic micafungin course at our institution. METHODS: A single-center, retrospective study was conducted between January 1, 2011, and July 31, 2017, to determine the IFI rate in patients receiving micafungin prophylaxis. Patients with suspected IFI were evaluated for probable or proven infection based on European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group Consensus Group invasive fungal disease definitions. Statistical analyses were descriptive. RESULTS: A total of 170 prophylactic micafungin courses from 129 unique patients ages <12 years at a median dose of 3 mg/kg daily were identified. The rate of probable or proven breakthrough IFIs was 2.4% as determined by clinical, radiologic, microbiologic, and histopathologic criteria. CONCLUSIONS: A low rate of breakthrough IFI was seen with micafungin prophylaxis that is consistent with prior published adult hematopoietic stem cell transplantation studies. Micafungin was well tolerated, with liver function test elevations being transient in most cases and thought to be related to alternative factors.Keywords
This publication has 28 references indexed in Scilit:
- Epidemiology of paediatric invasive fungal infections and a case‐control study of risk factors in acute leukaemia or post stem cell transplantBritish Journal of Haematology, 2010
- Safety and Pharmacokinetics of Repeat-Dose Micafungin in Young InfantsClinical Pharmacology & Therapeutics, 2009
- Pharmacokinetics of an Elevated Dosage of Micafungin in Premature NeonatesThe Pediatric Infectious Disease Journal, 2009
- Micafungin Versus Liposomal Amphotericin B for Pediatric Patients With Invasive CandidiasisThe Pediatric Infectious Disease Journal, 2008
- Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus GroupClinical Infectious Diseases, 2008
- Population Pharmacokinetics of Micafungin in Pediatric Patients and Implications for Antifungal DosingAntimicrobial Agents and Chemotherapy, 2007
- Safety, Tolerability, and Pharmacokinetics of Micafungin (FK463) in Febrile Neutropenic Pediatric PatientsAntimicrobial Agents and Chemotherapy, 2005
- Invasive Fungal Infections in Pediatric Oncology PatientsJournal of Pediatric Hematology/Oncology, 2005
- Micafungin versus Fluconazole for Prophylaxis against Invasive Fungal Infections during Neutropenia in Patients Undergoing Hematopoietic Stem Cell TransplantationClinical Infectious Diseases, 2004
- Five‐year‐survey of invasive aspergillosis in a paediatric cancer centre. Epidemiology, management and long‐term survivalMycoses, 1999